GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS)
- Orphan Drug Designation Granted from FDA for Epidiolex for the Treatment of IS - - Phase 3 Trial Expected to Commence in Q4 2016 - LONDON, June 21, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a …